Twinlab reported FY 2024 net sales of USD 11.7 million (-14.0%) and gross profit of USD 3.9 million (-22.0%), reflecting production backlogs at manufacturers that extended lead times, reduced demand from some major customers, and higher product input costs. Selling expenses were USD 0.5 million (-60.0%) as the company reduced advertising costs and did not have a major product launch, while general and administrative expenses were USD 5.2 million (0%). Twinlab posted a loss from operations of USD 1.8 million and a total net loss of USD 9.5 million for FY 2024; interest expense, net was USD 8.0 million. Twinlab ended FY 2024 with cash of USD 0.1 million, an accumulated deficit of USD 379.6 million, a working capital deficiency of USD 149.9 million, and total debt of USD 93.9 million (USD 91.7 million related-party), with USD 93.9 million of debt presented in current liabilities. The company said conditions including liquidity constraints, recurring losses, and litigation seeking approximately USD 1.0 million in damages raise substantial doubt about its ability to continue as a going concern within one year, and it is evaluating strategic alternatives including settlement negotiations, additional capital raising, refinancing, and other restructuring options, potentially including bankruptcy filings. Twinlab also highlighted wind-down and cost-reduction actions, including the earlier cessation of operations associated with NutraScience Labs and surrendering multiple office locations, and said it is focusing on its core branded supplement and natural products business across Twinlab, Reserveage, ResVitale, Metabolife, and Alvita.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twinlab Consolidated Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-26-000426), on March 03, 2026, and is solely responsible for the information contained therein.